Korean J Med.  2011 Nov;81(5):562-568.

Treatment of Advanced Hodgkin Lymphoma

Affiliations
  • 1Division of Hemato-Oncology, Department of Internal Medicine, KonKuk University School of Medicine, Seoul, Korea. sykim@kuh.ac.kr

Abstract

The major portion of Hodgkin lymphoma (HL) patients, even at an advanced stage can be cured with optimal initial treatment. ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the standard treatment regimen for the advanced stage HL, while Stanford V (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone) and escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) can be reasonable alternatives for selected patients. Although radiotherapy is the key component in Stanford V regimen, radiotherapy should be applied only at the residual lymphoma in patients who received ABVD and BEACOPP therapy. These three representative treatments for advanced HL have individual advantages and disadvantages, so that the choice of the initial treatment should be dependent on patients' relapse risk, comorbidity, and age.

Keyword

Hodgkin lymphoma; Treatment; Chemotherapy; Radiotherapy

MeSH Terms

Bleomycin
Comorbidity
Cyclophosphamide
Doxorubicin
Etoposide
Hodgkin Disease
Humans
Lymphoma
Mechlorethamine
Procarbazine
Recurrence
Vinblastine
Vincristine
Bleomycin
Cyclophosphamide
Doxorubicin
Etoposide
Mechlorethamine
Procarbazine
Vinblastine
Vincristine
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr